News publication
Everything we hold that Biotech Dispatch published.
Every article we hold from Biotech Dispatch.
Neurizon Therapeutics appoints Chris Bremer as CEO while interim executive chairman Sergio Duchini becomes non-executive chairman, with the company's ALS drug awaiting Phase 2/3 trial results in 2027.
Melbourne biotech Paradigm Biopharmaceuticals appointed FTI Consulting administrators after its Phase 3 trial failed an interim efficacy threshold, and now seeks to restructure debts via a deed of company arrangement.
Telix Pharmaceuticals has agreed to merge with German isotope producer ITM in a US$1.65 billion upfront deal, with contingent payments of up to US$700 million, creating a combined radiopharmaceutical group.
Under Business News Australia ·leads this story in the feed
Biotech Paradigm Biopharmaceuticals appoints rheumatology specialist Daniel Furtner as chief medical officer; predecessor Donna Skerrett stays as senior scientific advisor, and the firm's late-stage osteoarthritis trial has finished enrolling 538 participants.
Telix Pharmaceuticals has gained US regulatory clearance for its glioma imaging agent Pixclara, a world first, and is now studying the compound in late-stage trials for brain metastases.
America's NIH has agreed to fund a program giving up to 200 ALS patients access to Neurizon Therapeutics' drug NUZ-001, with Melbourne-based Neurizon as subawardee and a Boston ALS centre running it.
OncoSil Medical says a Madrid hospital has treated its 100th Spanish pancreatic cancer patient with its brachytherapy device, as the ASX-listed company focuses on deepening use across its 11 treatment sites.
OncoSil Medical has raised $5.6m from three large existing shareholders to fund overseas and domestic launches of its radiation therapy, after winning TGA and FDA clearances for pancreatic and bile duct cancer use.
Neurizon Therapeutics, a Melbourne biotech developing an ALS treatment, has appointed industry veteran Dr Chris Bremer as CEO as its lead drug NUZ-001 heads toward Phase 2/3 trial results in 2027.
Arovella Therapeutics has produced its first clinical batch of ALA-101, a donor-derived cell therapy for blood cancer, and begun trials at a Melbourne hospital, with the first patient expected to be dosed this month.
Melbourne biotech ENA Respiratory has received $2.98 million from incubator Biointelect Venturer's first investment round, one of six companies backed, funding a Phase Ib asthma study of its INNA-051 antiviral nasal spray.
Under Brandon Capital portfolio ·leads this story in the feed
Melbourne biotech Percheron Therapeutics has locked in $2.3 million through an institutional placement to fund a Vanderbilt Health trial of its HMBD-002 antibody in blood cancers.
An Australian infectious-disease incubator has selected six local biotechs to divide $10.48 million from its inaugural funding round, pairing non-dilutive cash with commercialisation support; the program is backed by an earlier MRFF grant.
Alterity Therapeutics has appointed MST Financial Services to backstop its expiring listed options ahead of a pivotal Phase 3 trial of its lead drug candidate for a rare neurodegenerative disorder.
Mesoblast's yearly report shows revenue leaping on first-year American sales of Ryoncil, losses narrowing, and a US$125 million debt refinancing, with its spinal disc trial fully recruited ahead of 2027 data.
Entropy Neurodynamics has agreed with UCSF to run a US Phase 2 trial of its psilocin drug TRP-8803 against escitalopram in young adults with depression, pending FDA clearance, with Swinburne and BioCina supporting.
Melbourne biotech Starpharma grew annual revenue on a Genentech licence payment, cut its loss, and completed a $30 million entitlement offer, giving it cash into 2028 to advance its cancer pipeline.
The two diagnostics companies have entered early-stage merger talks aiming to combine rapid pathogen testing with gut microbiome analysis, though both stress the discussions are preliminary with no terms agreed.
European regulators have cleared Neuren's Rett syndrome drug DAYBU, the first such treatment authorised in the EU, with milestone payments due to the Melbourne biotech from licence partner Acadia.
Acrux has hired Dr Jolanta Airey as chief medical officer, adding clinical leadership as the company prepares late-stage trials in the United States for its women's testosterone therapy.
Avecho Biotechnology brings in a former CSL dealmaking executive as a consultant to help license its Phase 3 CBD insomnia capsule internationally.
Mesoblast has finished dosing all 350 patients in its phase 3 trial of rexlemestrocel-L for degenerative disc disease, with data due mid-2027 and a possible US biologics application to follow.
Australian device maker OncoSil Medical has won US FDA humanitarian exemption approval for its targeted radiation treatment for unresectable distal bile duct cancer, opening a path to American commercialisation in financial year 2027.
Sydney biotech Biotron reports lab results showing its hepatitis B drug candidate works against HBV and HDV, and will begin formal preclinical studies ahead of planned human trials in 2027.
Six Australian health tech startups received a combined $13.5 million in non-dilutive funding from the CUREator+ program, supported by the Australian Government.
Starpharma wrapped up its $32 million shareholder rights issue with roughly 99% participation, with proceeds earmarked for first-in-human testing of its DEP HER2-Lutetium cancer therapy.
Under kalkine.com.au ·leads this story in the feed
Percheron Therapeutics has appointed Arovella Therapeutics' former leader Michael Baker as CEO from October, with James Garner departing for an overseas role while joining the board as a non-executive director.
Starpharma has launched a shareholder entitlement offer of about A$32 million, underwritten by Canaccord Genuity, to fund a Phase 1 cancer study and broaden its dendrimer oncology pipeline.
Under kalkine.com.au ·leads this story in the feed
Adelaide medtech Ferronova added $6 million to its Series A for image-guided cancer surgery, led by Uniseed/UniSuper, South Australian Venture Capital Fund, Artesian and Renew Pharmaceuticals; Renew's parent UltraGreen.ai recently listed in Singapore.
Under Uniseed ·leads this story in the feed
Deals recorded from Biotech Dispatch's coverage. A round is listed once, however many of their articles mention it.
| Company | Stage | Announced | Amount | Investors |
|---|---|---|---|---|
| Proboxis Biotechnology | Accelerator | 30 Aug 2026 | $1.5m | |
| Ebivanta Therapeutics | Accelerator | 30 Aug 2026 | $1.5m | |
| Percheron Therapeutics | Unnamed stage | 31 Aug 2026 | $2.3m | |
| ENA Respiratory | Grant | 1 Sep 2026 | $3m | |
| Ferronova | Series A | 17 Dec 2025 | $6m | |
| ENA Respiratory | Accelerator | 30 Aug 2026 | $8.3m | |
| Starpharma | Unnamed stage | 4 Aug 2026 | $32m | |
| Neurizon Therapeutics Limited | Grant | 9 Sep 2026 | - | |
| AdaptiVax | Accelerator | 30 Aug 2026 | - | |
| Saccharide Therapeutics | Accelerator | 30 Aug 2026 | - | |
| SAMMvax | Accelerator | 30 Aug 2026 | - |
Companies named in Biotech Dispatch's articles, most-covered first.
| Company | What it does | Articles |
|---|---|---|
| CSL | Biotechnology company partnering on the Jumar Bioincubator grant | 3 |
| Neurizon Therapeutics Limited | Focused on revolutionising treatment of neurodegenerative diseases. | 3 |
| OncoSil Medical | Australian medical-device company developing targeted radiation treatments | 3 |
| Starpharma | Melbourne-based biotech company advancing DEP HER2-Lutetium oncology program | 3 |
| US Food and Drug Administration | 3 | |
| Arovella Therapeutics | Company repositioned around cell therapy technologies and built an oncology pipeline | 2 |
| ENA Respiratory | Antiviral nasal spray to prevent severe respiratory viral infections | 2 |
| Grünenthal | German drug maker | 2 |
| Medical Research Future Fund | 2 | |
| Mesoblast | 2 | |
| Paradigm Biopharmaceuticals | 2 | |
| Percheron Therapeutics | Biotech company developing VISTA targeting checkpoint inhibitor HMBD-002 | 2 |
| Telix Pharmaceuticals | 2 | |
| United States Food and Drug Administration (FDA) | 2 | |
| Abbott | 1 | |
| AbbVie | 1 | |
| Acrux | 1 | |
| AdaptiVax | Working on a virus-like particle vaccine platform initially targeting RSV, human metapneu… | 1 |
| Aleris Therapeutics | 1 | |
| Alterity Therapeutics | biotechnology company developing disease-modifying treatments for neurodegenerative disor… | 1 |
| ANDHealth | Accelerates commercialisation of evidence-based digital and connected health technologies… | 1 |
| Avecho Biotechnology | 1 | |
| BioCina | 1 | |
| BioScience Managers | Company where Dr Baker previously held executive roles | 1 |
| Biotron | 1 | |
| Blue Ocean Equities | Joint lead manager for placement | 1 |
| Brandon BioCatalyst | Investment fund and incubator for biomedical research discoveries | 1 |
| Canaccord Genuity | 1 | |
| CUREator+ | 1 | |
| Cyclotek | Joint operator of OncoSil's Sydney manufacturing facility | 1 |
| Cygnet Capital | Joint lead manager for placement | 1 |
| Cynata Therapeutics | 1 | |
| Ebivanta Therapeutics | Developing an mRNA vaccine against Epstein–Barr virus. | 1 |
| European Commission | Granted marketing authorisation for DAYBU | 1 |
| Federal BioMedTech Horizons Program | 1 | |
| Ferronova | advance image-guided cancer surgery | 1 |
| Flinders Medical Centre | 1 | |
| Frontier Inflammasome Therapeutics | 1 | |
| FTI Consulting | 1 | |
| Genetic Signatures | Develops PCR-based infectious disease tests under its EasyScreen brand | 1 |
| Hospira | 1 | |
| Hospital HM Sanchinarro | Madrid hospital where the landmark 100th patient was treated | 1 |
| Imperial College London | University from which Arovella licensed its invariant natural killer T cell platform | 1 |
| INSEAD | 1 | |
| ITM Isotope Technologies Munich | 1 | |
| La Trobe University | University from which AlleSense was spun out. | 1 |
| Luma Bio | 1 | |
| Mass General Brigham | 1 | |
| Melbourne Business School | 1 | |
| Microba Life Sciences | Provides clinical-grade gut microbiome testing and has a therapeutics pipeline | 1 |
| MST Financial Services | 1 | |
| Navier Medical Ltd | 1 | |
| Neuren Pharmaceuticals | Melbourne-based biotechnology company developing therapies for serious neurological disor… | 1 |
| Neurotologix | 1 | |
| NIH | 1 | |
| Obsidian | 1 | |
| Peter MacCallum Cancer Centre | Cancer research and treatment centre in Melbourne | 1 |
| Proboxis Biotechnology | Developing a vaccine production platform for mosquito-borne viruses, beginning with Japan… | 1 |
| Radiopharm Theranostics | Company where Dr Baker was a non-executive director between 2021 and 2024 | 1 |
| Royal Adelaide Hospital | 1 | |
| SA Government | 1 | |
| Saccharide Therapeutics | Advancing ST101, a malaria vaccine designed to target a structure that remains consistent… | 1 |
| SAMMvax | Received support for TriVax, a trivalent vaccine designed to provide broad protection aga… | 1 |
| Sean M Healey and AMG Center for ALS | ALS centre at Mass General Brigham in Boston | 1 |
| Sonic Healthcare | Has distribution relationships with Microba | 1 |
| Swinburne University of Technology | 1 | |
| The Alfred Hospital | Melbourne hospital hosting the first trial site for Arovella's ALA-101 study | 1 |
| Therapeutic Goods Administration | Australia's medical device regulator, which approved the OncoSil device | 1 |
| Ultragreen.ai | Focuses on fluorescence-guided surgery | 1 |
| WeGuide | 1 |
Investors named in Biotech Dispatch's articles, most-covered first.
| Investor | What it does | Articles |
|---|---|---|
| Biointelect Venturer | A national incubator intended to help turn early-stage infectious disease research into i… | 2 |
| Artesian VC | Alternative asset management for debt and venture capital | 1 |
| Australian Ethical Investment | Ethical superannuation and managed investment funds | 1 |
| Canaccord Genuity Australia | 1 | |
| National Institutes of Health | US health agency | 1 |
| Regal Partners | Institutional investor and one of OncoSil Medical's biggest shareholders | 1 |
| Renew Pharmaceuticals | Subsidiary of Singapore-based Ultragreen.ai | 1 |
| South Australian Venture Capital Fund | 1 | |
| Uniseed/UniSuper | 1 |